RecruitingPhase 3

A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type II

United States4 participantsStarted 2022-07-28

Plain-language summary

The primary objective of this study is to evaluate the efficacy and safety of AVTX-803 compared to withdrawal in patients with Leukocyte Adhesion Deficiency, Type II (LAD II).

Who can participate

Age range6 Months – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Non-lactating and has a negative pregnancy test at screening -AND-
✓. Uses an acceptable double-barrier method of contraception as determined by the investigator or sub-investigator for the duration of the study and 30 days following the last dose of study drug.

What they're measuring

Effect of AVTX-803 on the percent of leukocytes expressing Sialyl-Lewis X antigen

Timeframe: Change from Baseline at Day 56, Change from Baseline at Day 112

Trial details

NCT IDNCT05462587

SponsorAUG Therapeutics

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-11-30

Contact for this trial

Jennifer Lin

3052833827 huiyil@augtx.com

View on ClinicalTrials.gov More Leukocyte Adhesion Deficiency trials